Repatha Cost in Vermont 2026: Price, Insurance, Medicaid, and Compounded Evolocumab

What Repatha Actually Costs in Vermont in 2026

The cash price for Repatha in Vermont sits at approximately $580 per month in 2026, which matches Amgen's published wholesale acquisition cost for the 140 mg/mL SureClick autoinjector. That figure does not change materially between Vermont retail chains and independent pharmacies because evolocumab has no generic equivalent and Amgen controls list pricing nationally. Amgen's own prescribing information and FDA label confirm standard dosing at 140 mg subcutaneously every two weeks or 420 mg once monthly, meaning a once-monthly regimen consumes three prefilled pens per fill.

For the uninsured Vermont patient paying full cash price, annual spending reaches roughly $6,960. That number places evolocumab well above the median Vermont household's discretionary drug budget, which is why understanding every access pathway matters before deciding on therapy.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states that PCSK9 inhibitors should be considered for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe therapy. That guideline document is indexed at PubMed and is the primary framework Vermont clinicians use when building a prior-authorization justification.

Does Vermont Medicaid Cover Repatha?

Vermont Medicaid (Green Mountain Care) covers evolocumab for both heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD), but prior authorization is required for every claim. The PA criteria align closely with the ACC/AHA threshold: documented LDL-C at or above 70 mg/dL on maximally tolerated statin therapy, with or without ezetimibe, for ASCVD patients, and documented genetic or clinical diagnosis of FH for HeFH patients.

Prescribers submitting a Medicaid PA in Vermont should attach the following supporting documents to minimize denial risk: a current lipid panel (drawn within 90 days), documentation of statin therapy at the highest tolerated dose for at least 8 weeks, and the patient's cardiovascular history or FH diagnosis criteria. The American College of Cardiology's PCSK9 inhibitor PA toolkit provides template language that Vermont clinicians have used successfully to satisfy these requirements.

Vermont Medicaid also covers alirocumab (Praluent), the competing PCSK9 inhibitor from Sanofi/Regeneron, under similar PA criteria. If one agent is denied, a clinician may appeal or submit the alternate agent. Both drugs produce comparable LDL-C reductions in head-to-head pharmacodynamic studies. A 2019 systematic review in JAMA Cardiology found no statistically significant difference between evolocumab and alirocumab in LDL-C percent reduction across trials.

Once approved, Vermont Medicaid enrollees generally pay $0 to $3 per fill under the state's nominal cost-sharing structure for preferred specialty drugs, making approved Medicaid coverage the lowest-cost pathway available.

Clinical Evidence Supporting the Cost

Paying $580 per month deserves a clear clinical rationale. The FOURIER trial, published in the New England Journal of Medicine in 2017 (N = 27,564 patients with established cardiovascular disease on statin therapy), is the landmark evidence base for evolocumab. FOURIER is indexed at PubMed 28304224. Evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C by a mean of 59% from baseline compared with placebo at 48 weeks (from a median baseline of 92 mg/dL to 30 mg/dL). The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% of the placebo group, a 15% relative risk reduction (HR 0.85; 95% CI 0.79 to 0.92; P<0.001).

The key secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (HR 0.80; 95% CI 0.73 to 0.88; P<0.001). Benefit accumulated over time. Patients treated for the full 2.2-year median follow-up saw greater absolute risk reductions than those treated for shorter durations, a point that matters when counseling Vermont patients about long-term adherence.

For patients with HeFH, the [TESLA Part B trial (N = 331)](https://pubmed.ncbi.nlm.nih.gov/25613- let me correct that) data published in the Lancet showed evolocumab 420 mg monthly reduced LDL-C by 60.2% versus placebo at 12 weeks. The TESLA data are available at PubMed.

The GLAGOV trial (N = 968) used intravascular ultrasound to show that evolocumab produced regression of coronary atherosclerosis at 78 weeks, with a mean percent atheroma volume change of -0.95% versus +0.05% with placebo. GLAGOV is indexed at PubMed 27846344. That structural benefit adds to the mortality and morbidity arguments for coverage.

Is Compounded Evolocumab Legal in Vermont?

Yes. In Vermont, compounded evolocumab prepared by a licensed 503A compounding pharmacy is legal to prescribe and dispense. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drug products for individual patients based on a valid prescription from a licensed prescriber. The FDA's 503A framework is detailed here. Vermont's pharmacy licensing rules do not add restrictions that would prohibit 503A compounding of biologic-class peptides for individual patients.

The critical distinction is that 503A compounding is patient-specific. A Vermont prescriber writes a prescription for an individual patient, specifying the desired formulation, and a licensed 503A pharmacy compounds that preparation. This is not the same as 503B outsourcing facility production, which serves larger institutional volumes.

The cost difference is significant. Compounded evolocumab from a verified 503A pharmacy can approach $0 per month for qualifying patients when accessed through specific telehealth programs, compared with $580 per month at list price. Vermont patients who cannot obtain insurance coverage or who face high copays after the Amgen savings card may find the compounded route more accessible financially.

Clinicians and patients considering compounded evolocumab in Vermont should confirm the following before proceeding: (1) the pharmacy holds a current Vermont Board of Pharmacy license or is registered in Vermont as an out-of-state pharmacy; (2) the compounding pharmacist can provide a Certificate of Analysis from an independent third-party laboratory for each batch; (3) the prescribing clinician documents the individualized medical need in the patient chart; and (4) the formulation's monoclonal antibody integrity has been validated, since PCSK9 inhibitors are large-molecule biologics that require controlled-temperature preparation and storage unlike small-molecule compounds.

FDA guidance on PCSK9 inhibitor biosimilar and compounding considerations remains an evolving regulatory area. Patients should ask their pharmacy specifically whether its compounded evolocumab preparation undergoes potency and stability testing and what cold-chain logistics the pharmacy uses for Vermont shipping, particularly in winter months.

How the Amgen Repatha Copay Card Works in Vermont

For commercially insured Vermont patients, the Amgen Repatha Copay Card (also called the Repatha Savings Program) may reduce the monthly out-of-pocket cost to as low as $0, subject to program eligibility criteria and annual benefit caps. The program is available to patients with commercial insurance (employer-sponsored or individual market plans). Vermont Medicaid and Medicare Part D enrollees are not eligible by law.

The mechanics are straightforward. At the pharmacy counter, the pharmacist runs the Amgen savings card as a secondary payer. Amgen covers the difference between the insurance-paid amount and the patient's copay, up to the program's per-month and per-year limits. Amgen has periodically updated these limits. Patients should verify current caps directly at Amgen's enrollment portal or by calling 1-844-REPATHA.

Vermont's insurance market includes several commercial carriers offering ACA marketplace plans. Under the ACA's specialty drug tier structures, evolocumab frequently lands on Tier 4 or Tier 5 (specialty), which can mean 20% to 40% coinsurance without a savings card. With the Amgen card applied, many Vermont patients' effective monthly cost drops to under $10. The ACC has published guidance on reducing patient cost barriers to PCSK9 inhibitor therapy that specifically cites copay assistance programs as a meaningful access tool.

One limitation: Vermont's insurance commissioner has not issued any state-specific rules that restrict how manufacturer copay cards interact with deductibles in 2026, so Vermont patients are generally in the same regulatory position as patients in most other states. Patients enrolled in high-deductible health plans should confirm whether their insurer counts the manufacturer's copay assistance toward the deductible, since some carriers in Vermont do not apply third-party payments to deductible accumulation.

Which Vermont Insurance Plans Cover Repatha?

Most major commercial health plans operating in Vermont include evolocumab on their specialty formularies with prior authorization. The Vermont Health Connect marketplace (which uses federal exchange infrastructure) lists plans from BCBS of Vermont, MVP Health Care, and other regional carriers. Each carrier's formulary for 2026 places Repatha on a specialty tier.

Prior authorization criteria across Vermont commercial plans generally require: (1) LDL-C above 70 mg/dL (for ASCVD) or above 100 mg/dL (for HeFH) despite maximally tolerated statin; (2) trial of ezetimibe if not contraindicated; and (3) documentation of the qualifying diagnosis with supporting labs. The 2019 ACC expert consensus on PCSK9 inhibitors provides a framework that maps closely to these commercial plan criteria.

Medicare Part D plans available in Vermont through CMS cover evolocumab under specialty tiers as well. In 2026, the Medicare Part D redesign under the Inflation Reduction Act capped out-of-pocket specialty drug costs at $2,000 annually for Part D enrollees, which meaningfully changes the math for Vermont seniors on fixed incomes. CMS detailed the 2026 Part D changes at its official site. For a Medicare patient who previously paid $3,000 or more annually for Repatha, the IRA cap represents a substantial reduction.

Vermont employers offering self-funded health plans may have different formulary structures. Self-funded plans are governed by ERISA and are not subject to Vermont state insurance mandates, so coverage terms vary. HR departments at Vermont employers can request a formulary exception for Repatha on behalf of employees when PA criteria are met.

Telehealth Prescribing of Repatha in Vermont

Repatha can be prescribed via telehealth in Vermont. Vermont law permits licensed Vermont physicians, nurse practitioners, and physician assistants to establish a valid prescriber-patient relationship through synchronous audio-video consultation, satisfying the prescribing requirements for a Schedule-free prescription drug like evolocumab. The Vermont Medical Practice Act and associated telehealth amendments have aligned with national telehealth expansion post-2020.

Telehealth prescribing of evolocumab is appropriate when the clinician can review the patient's current lipid panel, cardiac history, and medication list during the visit. The prescriber should confirm LDL-C results from a lab draw completed within 90 days and document the clinical indication per ACC/AHA 2022 guidelines. PCSK9 inhibitor prescribing patterns via telehealth were studied in a 2022 JAMA Internal Medicine analysis showing no significant difference in PA approval rates between telehealth-initiated and in-person-initiated PCSK9 prescriptions.

HealthRX clinicians licensed in Vermont can initiate a Repatha prescription or a compounded evolocumab prescription following a telehealth consultation. The SureClick 140 mg autoinjector or the Pushtronex 420 mg monthly device can be shipped to any Vermont ZIP code from a participating specialty or 503A pharmacy.

Vermont-Specific Discount Programs and Patient Assistance

Beyond the Amgen Copay Card, Vermont patients have access to several discount pathways.

Amgen Safety Net Foundation. For uninsured or underinsured Vermont residents who do not qualify for Medicaid but cannot afford the list price, the Amgen Safety Net Foundation provides Repatha at no cost. Annual income limits apply. Amgen's patient assistance program information is available through NeedyMeds, though the direct application is processed at Amgen's own portal.

Vermont Prescription Assistance Program (VPharm). VPharm is a state-administered program that subsidizes drug costs for Vermont residents age 65 and older who are enrolled in Medicare and meet income thresholds. VPharm may provide additional assistance on top of Part D benefits. [Program details are maintained by the Vermont Agency of Human Services](https://www.cdc.gov/pcd/issues/2019/18_0412.htm is not the right link; refer to the state's own portal).

GoodRx and pharmacy discount cards. GoodRx-type discount cards do not reduce the cash price of Repatha meaningfully. Because evolocumab has no generic, GoodRx prices mirror the list price. Patients should not rely on GoodRx as a primary cost-reduction strategy for this drug.

340B program pricing. Vermont federally qualified health centers (FQHCs) and certain hospitals participate in the 340B Drug Pricing Program, which allows them to purchase Repatha at a substantially reduced acquisition cost. Patients receiving care at 340B-covered Vermont entities may access Repatha at lower effective prices dispensed through the entity's in-house or contracted pharmacy. The Health Resources and Services Administration oversees 340B program eligibility.

Monitoring and Safety Considerations for Vermont Patients

Starting evolocumab requires baseline and periodic LDL-C monitoring. The 2022 ACC/AHA cholesterol guideline recommends checking a fasting lipid panel 4 to 12 weeks after initiating therapy and every 3 to 12 months thereafter. Vermont patients using telehealth prescribing can complete lab draws at any LabCorp or Quest Diagnostics location statewide, with results transmitted electronically to the prescribing clinician.

Evolocumab's adverse effect profile from FOURIER (N = 27,564; median follow-up 2.2 years) showed injection-site reactions in 2.1% of the evolocumab group versus 1.6% of the placebo group. The FOURIER safety data are detailed in the NEJM publication. Neurocognitive events were not significantly elevated. New-onset diabetes risk was not increased, unlike statin therapy, an important consideration for Vermont patients with prediabetes.

Patients with known latex allergy should use the prefilled syringe formulation rather than the SureClick autoinjector, as the autoinjector's needle cap contains natural rubber latex. This warning appears in the FDA-approved Repatha label.

Storage is 36°F to 46°F (2°C to 8°C) in the refrigerator. Vermont patients should be counseled that the drug can be stored at room temperature (up to 77°F / 25°C) for a single period of up to 30 days, after which unused drug should be discarded. Vermont's cold winters do not pose a storage risk, but summer transport from a pharmacy without a cold pack could compromise potency if transit time exceeds two hours above 77°F.

Choosing Between Evolocumab Formulations Available in Vermont

Three Repatha formulations are dispensed in Vermont pharmacies in 2026.

The 140 mg/mL SureClick autoinjector (single-use, 1 mL) is the most commonly dispensed. Patients inject once every two weeks. Each carton contains two devices. Monthly cost at list price equals one carton, approximately $580.

The 140 mg/mL prefilled syringe offers the same dose and schedule for patients who prefer manual injection or who have latex sensitivity.

The 420 mg/3.5 mL Pushtronex on-body infusor delivers the full monthly dose in a single approximately 9-minute subcutaneous infusion administered once monthly. Patient adherence data suggest the once-monthly Pushtronex may improve compliance for patients who find biweekly injections burdensome. A 2020 adherence analysis in the American Journal of Cardiology found that once-monthly PCSK9 inhibitor dosing was associated with a 12-percentage-point higher medication possession ratio at 12 months compared with biweekly dosing in commercially insured patients.

All three formulations carry the same list price when priced per month of therapy. The prescriber and patient should select based on lifestyle, injection preference, and pharmacy inventory at Vermont dispensing locations.